| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/JM9909443 |
| P698 | PubMed publication ID | 10882357 |
| P50 | author | Stefano Ferrari | Q39662003 |
| P2093 | author name string | F Hofmann | |
| D Stover | |||
| E Buchdunger | |||
| G Bold | |||
| G Martiny-Baron | |||
| J Frei | |||
| J Mestan | |||
| J Rösel | |||
| R Cozens | |||
| R Roth | |||
| M Lang | |||
| P Furet | |||
| K H Altmann | |||
| E Boss | |||
| J Brüggen | |||
| P Traxler | |||
| P W Manley | |||
| M Sills | |||
| E Masso | |||
| B Wietfeld | |||
| C Schlachter | |||
| F Acemoglu | |||
| L Lässer | |||
| R Emmenegger | |||
| W Vetterli | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2310-2323 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis | |
| P478 | volume | 43 |
| Q37170610 | A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). |
| Q42774694 | Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib. |
| Q35113656 | Advances in Molecular Therapies in Patients with Brain Tumors |
| Q36235571 | Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. |
| Q52942162 | Can we separate active from inactive conformations? |
| Q30477768 | Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish |
| Q43947457 | Classification of proteins based on the properties of the ligand-binding site: the case of adenine-binding proteins |
| Q47355318 | Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors. |
| Q42860072 | Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors |
| Q39965992 | Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines. |
| Q38701634 | Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes |
| Q39156144 | Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy |
| Q24670121 | Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome |
| Q39773388 | Discovery of potent vascular endothelial growth factor receptor-2 inhibitors |
| Q44043150 | Dissection of angiogenic signaling in zebrafish using a chemical genetic approach |
| Q80845934 | Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors |
| Q30168082 | From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents |
| Q46140420 | Functionalized alkenylzinc reagents bearing carbonyl groups: preparation by direct metal insertion and reaction with electrophiles |
| Q30978537 | Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching |
| Q45224240 | Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice |
| Q38694005 | Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling |
| Q34660821 | Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents |
| Q35840361 | Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. |
| Q35030176 | Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors |
| Q35747449 | N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors |
| Q54208644 | Organocatalytic Synthesis of Methylene-Bridged N-Heterobiaryls. |
| Q41197374 | PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling |
| Q33406444 | Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma |
| Q35703129 | Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) |
| Q39632305 | Pyridylmethylthio derivatives as VEGF inhibitors. Part 1 |
| Q35911472 | Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors |
| Q82733628 | Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors |
| Q36698678 | Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents |
| Q33847057 | Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents |
| Q39456618 | Synthesis and cytotoxic evaluation of some new phthalazinylpiperazine derivatives |
| Q38713930 | Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents |
| Q36450785 | Targeted approaches for the management of metastatic prostate cancer |
| Q38125442 | Targeting angiogenesis for treatment of human cancer |
| Q34495463 | Targeting angiogenesis with integrative cancer therapies |
| Q33872751 | The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents |
| Q37098747 | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties |
| Q38690911 | Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors |
| Q36158717 | Therapeutic targeting of receptor tyrosine kinases in lung cancer |
| Q41425182 | Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258 |
| Q35011885 | Therapies directed at vascular endothelial growth factor |
| Q37734455 | Translational therapies for malignant pleural mesothelioma. |
| Q34384638 | Tumor angiogenesis as a therapeutic target |
| Q34095776 | Tyrosine kinase inhibitors: from rational design to clinical trials |
| Q34451927 | VEGF antagonists |
| Q43168867 | VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures |
Search more.